(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 October 2012 (18.10.2012)

WIPO | PCT

(10) International Publication Number
WO 2012/140627 A1

(51) International Patent Classification:
C07K 14/705 (2006.01) *A61K 39/00* (2006.01)
C07K 14/715 (2006.01)

(21) International Application Number:
PCT/IB2012/051868

(22) International Filing Date:
16 April 2012 (16.04.2012)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/475,682 15 April 2011 (15.04.2011) US
61/532,575 9 September 2011 (09.09.2011) US
61/581,194 29 December 2011 (29.12.2011) US

(71) Applicant *(for all designated States except US)*: **COMPUGEN LTD.** [IL/IL]; 72 Pinchas Rosen St., 69512 Tel Aviv (IL).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **TOPORIK, Amir** [IL/IL]; 14 Marvad Haksamim St., Apt.19, 58847 Holon (IL). **NOVIK, Amit** [IL/IL]; 5 Habrosh St., 30500 Binyamina (IL). **SHEMESH, Ronen** [IL/IL]; 23/5 Hativat Givati St., 71700 Modiin (IL).


(74) Agents: **Dr. D. Graeser Ltd.** et al.; 13 HaSadna St., PO Box 2496, 43650 Ra'anana (IL).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

[Continued on next page]

(54) Title: POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER


LSR isoform-a (SEQ ID NO:11):



SP - aa 1-41: **MALLAGGLSRGLGSHPAAAGRDAVVFVWLLLSTWCTAPARA**

TM - aa 212-234: **WLFVVVVCLAAFLIFLLLGICWC**

LSR isoform-a ECD (without SP) - aa 42-211 (SEQ ID NO:12):



NA encoding LSR isoform-a ECD (SEQ ID NO:40):




FIG. 1E

(57) Abstract: This invention relates to LY6G6F, VSIG10, TMEM25 and LSR proteins, which are suitable targets for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders, and drug development. This invention further relates to soluble LY6G6F, VSIG10, TMEM25 and LSR molecules, extracellular domains of LY6G6F, VSIG10, TMEM25 and LSR and conjugates, which are suitable drugs for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders. This invention further relates to antibodies and antigen binding fragments and conjugates containing same, and/or alternative scaffolds, specific for LY6G6F, VSIG10, TMEM25 or LSR molecules, which are suitable drugs for immunotherapy, treatment of cancer, infectious disorders, and/or immune related disorders.

WO 2012/140627 A1

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*